二甲双胍与安慰剂对肝硬化门脉高压患者门脉压力的急性影响:随机临床研究
该随机双盲研究纳入32例肝硬化患者,对比单次口服1000mg二甲双胍(n=16)或安慰剂(n=16)前后90分钟HVPG变化。二甲双胍组HVPG平均相对变化为-16%(95%CI:-28%至-4%),安慰剂组为4%(95%CI:-6%至14%),组间时间交互P=0.008。基线HVPG≥12mmHg患者中,二甲双胍组46%(6/13)达到临床显著改善,安慰剂组为8%(1/13)(P=0.07)。
要点
- 单次口服二甲双胍1000mg可急性降低肝硬化门脉高压患者HVPG。
- HVPG平均相对变化二甲双胍组-16%,安慰剂组4%,组间交互P=0.008。
- 基线HVPG≥12mmHg者临床显著改善率46% vs 8%,但P=0.07未达统计学显著。
核心结论
- 单次口服二甲双胍可急性降低门脉高压患者的HVPG,且不改变全身或肝脏血流动力学及炎症标志物。
研究设计与样本
- 随机双盲研究,纳入32例肝硬化患者,二甲双胍组16例、安慰剂组16例,比较服药前与服药后90分钟HVPG及肝脏灌注。
主要发现
- HVPG平均相对变化二甲双胍组为-16%(95%CI:-28%至-4%),安慰剂组为4%(95%CI:-6%至14%),时间×组交互P=0.008。
- 基线HVPG≥12mmHg患者中,临床显著改善(HVPG<12mmHg或HVPG下降>20%)二甲双胍组46%(6/13),安慰剂组8%(1/13),P=0.07。
- 两组间全身血压、心率、肝血浆与血流量、肝脏ICG清除率、肝脏O2摄取及炎症标志物均无变化或差异。
关键数值与推荐
- 二甲双胍单次口服剂量1000mg,给药后90分钟评估HVPG。
- 临床显著改善定义为HVPG<12mmHg或HVPG下降>20%。
临床怎么用
- 二甲双胍可能作为安全廉价的降低HVPG的候选药物,但需更大规模长期结局临床研究验证。
局限性
- 样本量小(32例),仅评估单次给药后90分钟的急性效应,基线HVPG≥12mmHg亚组改善率组间比较P=0.07未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Portal hypertension is the main determinant of clinical decompensation in patients with liver cirrhosis. In preclinical data metformin lowers portal pressure, but there are no clinical data for this beneficial effect. AIMS: To investigate the acute effects of metformin on hepatic venous pressure gradient (HVPG) and liver perfusion. METHODS: In a randomised, double-blinded study design, we investigated 32 patients with cirrhosis before and 90 minutes after ingestion of 1000-mg metformin (n = 16) or placebo (n = 16). Liver vein catherisation was performed to evaluate HVPG and indocyanine green (ICG) infusion for investigation of hepatic blood flow. RESULTS: The mean relative change in HVPG was -16% (95% CI: -28% to -4%) in the metformin group compared with 4% (95% CI: -6% to 14%) in the placebo group (time × group interaction, P = 0.008). In patients with baseline HVPG ≥12 mm Hg clinically significant improvements in HVPG (HVPG <12 mm Hg or a >20% reduction in HVPG) were observed in 46% (6/13) of metformin-treated and in 8% (1/13) of placebo-treated patients (P = 0.07). There were no changes or differences in systemic blood pressure, heart rate, hepatic plasma and blood flow, hepatic ICG clearance, hepatic O2 uptake or inflammation markers between groups. CONCLUSIONS: A single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers. This offers a promising perspective of a safe and inexpensive treatment option that should be investigated in larger-scale clinical studies with long-term outcomes in patients with cirrhosis and portal hypertension.
引用
- Rittig N, Aagaard NK, Villadsen GE, et al. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2021. PMID: 34165199. doi:10.1111/apt.16460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。